Image

    Cutaneous Adverse Effects of Targeted Therapies

    January 2015 in “ Journal of the American Academy of Dermatology ”
    James B. Macdonald, Brooke Macdonald, Loren E. Golitz … Aleksandar Sekulić
    Studysummary This review discusses skin-related toxicities associated with targeted cancer therapies and emphasizes the need for dermatologists to understand and manage these adverse effects, but reports no new experimental results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaad.org →
    Discuss this study in the Community →

    Research cited in this study 15

    1. Understanding, Recognizing, and Managing Toxicities of Targeted Anticancer Therapies Ca · 2013
    2. Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia JAMA Dermatology · 2013
    3. A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib JAMA Dermatology · 2013
    4. Neutralization of IL-8 Prevents Dermatologic Adverse Events Associated with Epidermal Growth Factor Receptor Inhibition PLoS ONE · 2012
    5. Advances in the Management of Cutaneous Toxicities of Targeted Therapies Seminars in Oncology · 2012
    6. The Management of EGFR Inhibitor Adverse Events: A Case Series and Treatment Paradigm International Journal of Dermatology · 2012
    7. A Case of Cicatricial Alopecia Associated with Erlotinib Annals of Dermatology · 2011
    8. Cetuximab-Associated Elongation of the Eyelashes American Journal of Clinical Dermatology · 2010
    9. A Case Report of Inflammatory Nonscarring Alopecia Associated with the Epidermal Growth Factor Receptor Inhibitor Erlotinib Journal of Cutaneous Pathology · 2009
    10. Gefitinib-Induced Hair Alterations: Figure 1 BMJ Case Reports · 2009
    11. Skin Toxicity Caused by EGFR Antagonists: An Autoinflammatory Condition Triggered by Deregulated IL-1 Signaling? Journal of Cellular Physiology · 2008
    12. Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor Acta Dermato Venereologica · 2003
    13. Tyrosine Kinase Inhibition and Grey Hair The Lancet · 2003
    14. Expression of a Dominant Negative Mutant of Epidermal Growth Factor Receptor in the Epidermis of Transgenic Mice Elicits Striking Alterations in Hair Follicle Development and Skin Structure. The EMBO Journal · 1995
    15. Differences in Human Skin Between the Epidermal Growth Factor Receptor Distribution Detected by EGF Binding and Monoclonal Antibody Recognition Journal of Investigative Dermatology · 1985